A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

(2012) T A Yap et al.   BRITISH JOURNAL OF CANCER

Population Pharmacokinetic–Pharmacodynamic Analysis of Neutropenia in Cancer Patients Receiving PM00104 (Zalypsis®)

(2012) Mario González-Sales et al.   CLINICAL PHARMACOKINETICS

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

(2012) Christophe Massard et al.   INVESTIGATIONAL NEW DRUGS

Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients

(2011) Carlos Pérez-Ruixo et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Molecular pharmacology and antitumor activity of Zalypsis ® in several human cancer cell lines

(2009) Juan F.M. Leal et al.   BIOCHEMICAL PHARMACOLOGY

Zalypsis (PM00104) is a potent inducer of  -H2AX foci and reveals the importance of the C ring of trabectedin for transcription-coupled repair inhibition

(2009) J. Guirouilh-Barbat et al.   MOLECULAR CANCER THERAPEUTICS

Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks

(2008) E. M. Ocio et al.   BLOOD